Essential Oils for Sleep: Building an Evening Wind-Down Routine

Two thousand years before anyone measured a sleep latency, physicians were prescribing valerian root for insomnia. Hippocrates described its properties in the fifth century BCE. Dioscorides recommended it for sleep disturbance. Galen prescribed it. Medieval Europe called it all-heal and grew it in every monastery garden. During the Second World War, it was distributed in England to civilians sleeping through the air raids.

Spikenard runs older and further. Harvested from the high Himalaya, it appears in the Ayurvedic materia medica, in Egyptian burial preparation, in Greek and Hebrew record, and in the Gospels — where a woman breaks an alabaster jar of it and the room fills with the scent. It has been continuously used, across unconnected civilisations, for three thousand years.

That convergence is the point. Independent traditions, separated by oceans and centuries, reached for the same two roots for the same purpose. Modern trials have not caught up with them — and it is worth being precise about what that does and does not mean.

What the modern evidence establishes

Start with the finding that matters most, because it describes exactly how these oils work. In 2015, Lillehei and colleagues at the University of Minnesota randomised seventy-nine students with self-reported sleep problems. Every participant practised the same sleep hygiene protocol. Half also wore an inhalation patch containing lavender oil; half wore a blank patch. Both groups slept better. The lavender group slept better still — on the Pittsburgh Sleep Quality Index and on the NIH PROMIS scale — and the advantage was still measurable two weeks after the intervention ended. Sleep quantity did not change. Sleep quality did, and so did the odds of waking up feeling refreshed.

This is the finding to hold onto. The aromatic did not replace the routine. It amplified it.
Larger clinical work points the same direction. In a four-week randomised controlled trial in patients with chronic heart failure, published in the European Journal of Cardiovascular Nursing, the lavender group showed significantly better sleep quality at every measured timepoint. In postoperative neurosurgical patients, objective sleep monitoring — not questionnaires — recorded shorter sleep latency and fewer nocturnal awakenings.

And a 2023 systematic review in Complementary Therapies in Clinical Practice examined fifty randomised trials of inhalation aromatherapy in clinical settings. Lavender was the most-studied oil. Orange-family oils came next. In one of the trials reviewed, a lavender and sandalwood blend produced a significant reduction in anxiety compared with both an alternative blend and a placebo.

Neroli — the blossom of the bitter orange — carries its own body of work. In a randomised controlled trial conducted at the University of Naples Federico II, women in labour who received neroli inhalation reported significantly lower anxiety and perceived pain than controls at every stage. A 2025 trial in paediatric dentistry, using a lavender–neroli blend before anaesthesia, measured reductions in anxiety across facial-image scoring and vital signs.

The honest ceiling on all of this: aromatic trials cannot be blinded. Lavender smells like lavender. The heart-failure trial said so outright — only the outcome assessors were blind. Expectancy cannot be separated from effect. Lillehei’s design, with its blank patch, handled the problem better than most, which is part of why it remains the reference.
Real signal. Modest effect. A methodological ceiling nobody can raise.

Valerian and spikenard: where tradition runs ahead of the trials

Valerian’s mechanism is not in dispute. Valerenic acid modulates GABA-A receptors — the same receptor family targeted by benzodiazepines. Spikenard’s sesquiterpenes, jatamansone and nardosinone chief among them, show GABA-ergic activity in vitro. In rodents, inhaled valerian oil shortens sleep latency and extends total sleep. Spikenard rhizome does the same, and reduces spontaneous locomotor activity in open-field testing.

What does not exist is a controlled human trial of either root, inhaled, for sleep.

The clinical literature on valerian concerns oral extract at 300–600mg, and even there the record is contested — the US National Institutes of Health calls the trial evidence inconclusive. For spikenard, the position is starker: the published record is phytochemical and preclinical, and clinical trial data are lacking to recommend it for any indication.
This is the sentence most brands would bury. We think it belongs in the second paragraph, because the reason for the gap is not what it appears.

Nobody is going to fund a phase III trial of inhaled Himalayan rhizome oil. There is no molecule to patent at the end of it. Spikenard is CITES-restricted, slow to harvest, and expensive. The absence of trial data is an artefact of pharmaceutical economics, not a verdict on the plant. Three thousand years of continuous use across four unconnected medical traditions is evidence of a different kind — weaker than an RCT, and considerably stronger than nothing.

So why do we formulate with them?

Because both earn their place twice over. Valerian and spikenard are structural materials. They sit at the base of a composition, heavy and rooty and slow to evaporate, holding the lighter florals above them in place. A blend built on lavender alone smells bright for twenty minutes and then smells of nothing. Valerian gives it a floor.

And because the tradition is not decorative. When Ayurvedic practitioners, Greek physicians, and Himalayan herbalists independently converge on the same rhizome for the same purpose, the reasonable response is curiosity, not dismissal.

We would rather tell you that clearly than pretend a rodent study is a clinical trial.

The part that does the heavy lifting

Here the evidence is stronger than anything in the aromatics literature — and largely ignored by the industry, for reasons that are not difficult to work out.
Stop eating three hours before bed

A survey of 793 university students in Sydney found that eating within three hours of bedtime raised the odds of waking during the night by 61%; after adjustment for ethnicity and BMI, the association held at 43%. Sleep onset was unaffected. What changed was sleep continuity — the waking at 3am that most people describe as their real problem.
Analysis of American Time Use Survey data, published in the British Journal of Nutrition, found that eating or drinking within one hour of bedtime roughly doubled the odds of clinically significant wake-after-sleep-onset in both men and women.

The mechanism is unromantic. Reflux, gastric discomfort, and the fact that digestion runs less efficiently at night.

There is a useful wrinkle. Afaghi and colleagues found that a high-glycaemic-index meal eaten four hours before bed roughly halved sleep onset latency compared with the same meal eaten one hour before. The timing of carbohydrate matters as much as its presence.
Everything else in the protocol

The sleep-hygiene-only arm of the Lillehei trial improved. That protocol contains nothing exotic: a fixed bed and wake time, seven days a week. A cool, dark room. Screens away for the final hour. Caffeine finished by early afternoon. The bed used for sleep and nothing else.

None of it is interesting. All of it outperforms any oil ever bottled.

Why scent works: the cue, not the sedative

Here is the mechanism that actually explains the Lillehei result.
The olfactory bulb projects directly into the amygdala and hippocampus. Smell is the only sense that reaches memory and emotion without first passing through the thalamus. This is why a scent can return a room to you from thirty years ago, intact, unbidden, in half a second.

A distinctive aromatic, applied only in the twenty minutes before sleep and never otherwise, becomes a conditioned cue. Not a sedative — a signal. It tells a nervous system that has learned the pattern that the sequence has begun: the meal was hours ago, the lights are low, the phone is in another room.

The corollary is strict, and almost everyone violates it. A sleep scent must be used only for sleep. Wear it to dinner and the association degrades into background. A blend pleasant enough to wear all day is a blend that will stop working at night.

This is why we compose Sacred Rest to be unmistakable rather than agreeable. It is not a perfume.

Inside Sacred Rest

The carrier system. MCT coconut oil and jojoba absorb without residue — jojoba is technically a liquid wax ester, closer in structure to human sebum than most plant oils, which is why it sits rather than sits on the skin. Squalane adds slip without heaviness. Isopropyl myristate improves how the aromatics spread across the skin surface and takes away the greasy after-feel that heavy carriers leave behind.

The aromatic architecture. High-altitude lavender, selected for its elevated linalyl acetate — altitude shifts the ester profile, and the result is softer, rounder, less camphoraceous than lowland lavender. Roman chamomile. Neroli. Mysore sandalwood. Below them, the base: vetiver extracted by supercritical CO₂ rather than steam, preserving the heavy molecules that distillation drives off. Atlas cedarwood. Valerian root. Spikenard. Benzoin, a resinoid that acts as fixative — slowing the evaporation of everything above it so that the blend still smells like itself an hour later.

The antioxidant system. Mixed tocopherols and rosemary oleoresin extract. Neither contributes scent. Both slow the oxidation of unsaturated lipids in the carrier. This is a formulation decision, not a wellness one, and it is the correct pairing.

Nine aromatic materials. Four carriers. Two antioxidants. Every one of them is doing a job.

The routine, assembled

We are not going to tell you the oil is the most important line in that table. It is not. It is the line that makes the other four easier to keep — and since adherence is the entire problem with sleep hygiene, that is not a small thing to be.

SACRED REST 30ml by MAHASUTRA

THERAPEUTIC OILS THAT IS FORMULATED BY PROFESSIONALS